CA Patent

CA3223135A1 — Combination therapy treatment using transdermal delivery system

Assigned to Corium LLC · Expires 2023-01-05 · 3y expired

What this patent protects

The present disclosure provides a transdermal delivery system for treating Alzheimer's disease with donepezil, optionally in combination with a second therapeutic agent such as aducanumab.

USPTO Abstract

The present disclosure provides a transdermal delivery system for treating Alzheimer's disease with donepezil, optionally in combination with a second therapeutic agent such as aducanumab.

Drugs covered by this patent

donepezil-hydrochloride (DONEPEZIL HYDROCHLORIDE)

Patent Metadata

Patent number: CA3223135A1
Jurisdiction: CA
Classification: —
Expires: 2023-01-05
Drug substance claim: No
Drug product claim: No
Assignee: Corium LLC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.